Correction to: Development and validation of a modified albumin–bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab (Hepatology International, (2023), 17, 1, (86-96), 10.1007/s12072-022-10406-8)

On behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)

研究成果: ジャーナルへの寄稿コメント/討論

2 被引用数 (Scopus)

抄録

The Figs. 2 and 3 were erroneously labeled in the original publication of the article. ‘ALF score’ should be corrected as ‘mALF score’. The Figs. 2 and 3 should have appeared as shown below.

本文言語英語
ページ(範囲)271-273
ページ数3
ジャーナルHepatology International
17
1
DOI
出版ステータス出版済み - 2023/02

ASJC Scopus 主題領域

  • 肝臓学

フィンガープリント

「Correction to: Development and validation of a modified albumin–bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab (Hepatology International, (2023), 17, 1, (86-96), 10.1007/s12072-022-10406-8)」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル